RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

About this update from Rxsight, Inc.

[{"type":"image","alt":"RxSight, Inc.","displaySize":"","headline":null,"caption":"RxSight, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RlZbsYuiF8.V1Nc6BC4.Lw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4","width":300,"height":92}},"lazy":false},{"type":"text","content":"ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition.","length":449,"tagName":"p"},{"type":"text","content":"Preliminary Unaudited Fourth Quarter and Full-year 2025 Results","length":63,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Preliminary unaudited fourth quarter 2025 revenue is expected to be approximately $32.6 million, driven by:","length":107,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The sale of 28,611 Light Adjustable Lenses (LAL™/LAL+®); representing a 10% increase in procedure volume compared to the third quarter of 2025; and","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"The sale of 25 Light Delivery Devices (LDD™s), expanding the installed base to 1,134 LDDs as of December 31, 2025.","length":114,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":261,"olType":false}]},{"val":[{"type":"text","content":"Preliminary unaudited 2025 fiscal year revenue is expected to be approximately $134.5 million, versus November guidance of $125 to $130 million, reflecting:","length":156,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The sale of 109,615 LALs, representing a 12% increase in procedure volume compared to 2024; and","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"The sale of 163 LDDs.","length":21,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":116,"olType":false}]},{"val":[{"type":"text...

More updates from Rxsight, Inc.